2Osborne CK. Adjuvant endocrine therapy [M]//Harris,Lippman,Morrow, et al. Diseases of the breast. 3rd Ed. USA. Lippincott: Williams & Wilkins, 2004:865 - 891. 被引量：1
3Kaufman M, Jonat W, Blamey R, et al.Survival analyses fromm the ZEBRA study: goserelin(ZoladexTM) versus CMF in premenopausal woman with node-positive breast cancer [J]. Eur J Cancer, 2003,39(12):1711-1717. 被引量：1
4Marina Parton, Ian E. Smith. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women[J]. J Clin Oncol, 2008,26(5):745-752. 被引量：1
5ATAC Trialist' s Group. Effect of anastroznle and tamnxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial[J ]. Lancet Oncol, 2008, 9(1):45-53. 被引量：1
6Coates AS, Keshaviah A, Thiirlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for pnstmenopausal women with endocrine-responsive early breastcancer: update of study BIG 1-98 [J]. J Clin Oncol, 2007,25(5): 486-492. 被引量：1
7Coombes RC, Kilburn Lq, Snowdon CF, et al. Survival and safety of exemestane vs.tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial[ J ]. Lancet, 2007,369 ( 9561 ) :559-570. 被引量：1
8Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial [J]. Lancet, 2005,366 (9484): 455-462. 被引量：1
9Chlebowski RT. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormnne-receptorpositive early breast cancer [J]. Brea Cancer Res Treat,2008,112 (suppl 1 ):25-34. 被引量：1
10Jakesz R, Gnant M, Greil R, et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8 [J]. Brea Cancer Res Treat,2005,94(suppl 1): 10. 被引量：1
